Literature DB >> 10775486

Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice.

J D Bisognano1, H D Weinberger, T J Bohlmeyer, A Pende, M V Raynolds, A Sastravaha, R Roden, K Asano, B C Blaxall, S C Wu, C Communal, K Singh, W Colucci, M R Bristow, D J Port.   

Abstract

The beta(1)-adrenergic receptor (AR) is the dominant subtype in non-failing and failing myocardium. beta(1)-AR signaling, by the endogenous neurotransmitter norepinephrine, is central to the regulation of myocardial contractility. In heart failure, the beta(1)-AR undergoes subtype-selective downregulation which may protect against the increased cardiac adrenergic drive associated with this pathophysiological state. To examine the hypothesis that chronically increased beta(1)-AR mediated signaling has adverse myocardial effects, transgenic mice overexpressing the human beta(1)-AR in a cardiac-selective context were produced, utilizing an alpha-myosin heavy chain (MHC) promoter. In these mice, beta(1)-AR protein abundance was approximately 24-46-fold (1-2 pmol/mg protein) that of wild-type mice. Histopathological examination of young (4 months old) and old (approximately 9 months old) transgenic mouse hearts consistently demonstrated large areas of interstitial replacement fibrosis, marked myocyte hypertrophy and myofibrilar disarray. In addition, increased expression of the pre-apoptotic marker, Bax, was observed coincident with regions of fibrosis accompanied by an increased apoptotic index, as measured by TUNEL assay. Older non-transgenic mice exhibited a slight tendency towards a decreased fractional shortening, whereas older beta(1)-AR transgenic mice had a marked reduction in fractional shortening (%FS approximately 30) as determined by echocardiography. Additionally, older beta(1)-AR transgenic mice had an increased left ventricular chamber size. In summary, cardiac-directed overexpression of the human beta(1)-AR in transgenic mice leads to a significant histopathological phenotype with no apparent functional consequence in younger mice and a variable degree of cardiac dysfunction in older animals. This model system may ultimately prove useful for investigating the biological basis of adrenergically-mediated myocardial damage in humans. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10775486     DOI: 10.1006/jmcc.2000.1123

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  67 in total

Review 1.  Myocardial gene transfer.

Authors:  D C White; W J Koch
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

Review 2.  Beta-adrenergic receptors in the failing heart: the good, the bad, and the unknown.

Authors:  S B Liggett
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

Review 3.  A-kinase anchoring proteins that regulate cardiac remodeling.

Authors:  Graeme K Carnegie; Brian T Burmeister
Journal:  J Cardiovasc Pharmacol       Date:  2011-11       Impact factor: 3.105

Review 4.  β-Adrenergic receptor subtype signaling in heart: from bench to bedside.

Authors:  Anthony Yiu Ho Woo; Rui-ping Xiao
Journal:  Acta Pharmacol Sin       Date:  2012-01-30       Impact factor: 6.150

Review 5.  Calcium cycling proteins and their association with heart failure.

Authors:  L Hadri; R J Hajjar
Journal:  Clin Pharmacol Ther       Date:  2011-08-10       Impact factor: 6.875

6.  β-arrestin-biased signaling through the β2-adrenergic receptor promotes cardiomyocyte contraction.

Authors:  Richard Carr; Justin Schilling; Jianliang Song; Rhonda L Carter; Yang Du; Sungsoo M Yoo; Christopher J Traynham; Walter J Koch; Joseph Y Cheung; Douglas G Tilley; Jeffrey L Benovic
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-27       Impact factor: 11.205

7.  Alternative signaling: cardiomyocyte beta1-adrenergic receptors signal through EGFRs.

Authors:  Stefan Engelhardt
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

8.  Network-based predictions of in vivo cardiac hypertrophy.

Authors:  Deborah U Frank; Matthew D Sutcliffe; Jeffrey J Saucerman
Journal:  J Mol Cell Cardiol       Date:  2018-07-17       Impact factor: 5.000

9.  Adenylyl cyclase 6 deletion increases mortality during sustained β-adrenergic receptor stimulation.

Authors:  Tong Tang; N Chin Lai; Adam T Wright; Mei Hua Gao; Paul Lee; Tracy Guo; Ruoying Tang; Andrew D McCulloch; H Kirk Hammond
Journal:  J Mol Cell Cardiol       Date:  2013-04-12       Impact factor: 5.000

Review 10.  Sympathetic nervous system activity and ventricular tachyarrhythmias: recent advances.

Authors:  Kelley P Anderson
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-01       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.